Highlights
Dual-Mechanism Efficacy
APG-2449 acts as both a third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) and a focal adhesion kinase (FAK) inhibitor, addressing resistance pathways that often bypass traditional TKI therapy.
Overcoming Resistance in ALK-Positive NSCLC: The Emergence of APG-2449 as a Novel FAK and Third-Generation TKI
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.